Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness (FALD)
Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study
Sponsor: Mezzion Pharma Co. Ltd
Listed as NCT03430583, this PHASE3 trial focuses on Single Ventricle Heart Disease and remains completed. Sponsored by Mezzion Pharma Co. Ltd, it has been updated 19 times since 2018, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
19 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Completed PHASE3
Phase: None → PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Jun 2025 — Sep 2025 [monthly]
Completed
Status: Unknown → Completed
-
Sep 2024 — Jun 2025 [monthly]
Unknown
▶ Show 14 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Dec 2021 — Dec 2022 [monthly]
Active Not Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting
-
Feb 2020 — Nov 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — Feb 2020 [monthly]
Recruiting
-
Oct 2018 — Mar 2019 [monthly]
Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mezzion Pharma Co. Ltd
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .